The Traderszone Network

27 May, 2014 by The TZ Newswire Staff Comments Off on Aggressive Accounting and Secular Decline in ATM Market May Not Bode Well for Cardtronics

Aggressive Accounting and Secular Decline in ATM Market May Not Bode Well for Cardtronics

Author: 
Sahm Adrangi

Cardtronics could lose 7-Eleven as a customer after 2017, which would prove catastrophic to the ATM owner/operator.

27 May, 2014 by The TZ Newswire Staff Comments Off on Why Shares of EnerNOC, Inc. Popped Today

Why Shares of EnerNOC, Inc. Popped Today

Is this meaningful or just another movement?

read more

27 May, 2014 by The TZ Newswire Staff Comments Off on Shorts Are Piling Into These Stocks. Should You Be Worried?

Shorts Are Piling Into These Stocks. Should You Be Worried?

Do short-sellers have these three stocks pegged? You be the judge!

read more

27 May, 2014 by The TZ Newswire Staff Comments Off on 1 WTC tenant looking to halve its commitment

1 WTC tenant looking to halve its commitment

The China Center, the first private-sector tenant to sign on for office space at One World Trade Center, is negotiating to halve its commitment there, according to sources familiar with the…

To view the full story, click the title link.

27 May, 2014 by The TZ Newswire Staff Comments Off on American Express charges higher, Hillshire is hot

American Express charges higher, Hillshire is hot

Here’s a look at what tickers you’re searching for today and why they’re so hot.

27 May, 2014 by The TZ Newswire Staff Comments Off on Gold weakness suggests even lower prices

Gold weakness suggests even lower prices

Gold is breaking down out of a symmetrical triangle and the resulting price pattern looks bearish. Here’s the levels JC Parets is watching.

27 May, 2014 by The TZ Newswire Staff Comments Off on What the dead Pfizer/AstraZeneca deal means for M&A

What the dead Pfizer/AstraZeneca deal means for M&A

As is true in business so it is in life: just because someone really, really wants to be with you doesn’t mean you can play hard to get forever. After six-months of courting AstraZeneca, Pfizer announced that it had pulled its $118 billion offer and had no plans to attempt a hostile acquisition.